Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture
You may also be interested in...
Lack Of Device Identifiers On Recalled Cardiac Devices Cost Medicare $1.5Bn, OIG Says
Medicare lost $1.5bn in claims over a 10-year period to cover procedures to fix or replace seven faulty cardiac devices due to the lack of product-specific information on its claims form for malfunctioning defibrillators and pacemakers, says the US HHS Office of Inspector General. Recalls of Medtronic, Boston Scientific and Abbott/St. Jude Medical cardiac rhythm management devices are likely behind most of the cost.
ICD Lead Recall Could Have Come Sooner With Novel Surveillance Tool – Study
A retrospective analysis shows that a software analytics tool would have enabled earlier detection of Medtronic’s Sprint Fidelis defibrillator lead fracture issues and an earlier recall of the device, which was withdrawn from the market in 2007.
Exit Interview: Medtronic CEO Hawkins Sees Burgeoning Challenges, Opportunities
In an environment impacted by health care reform and an increasingly complex reimbursement arena, device trials must demonstrate both clinical and economic utility equally, said Bill Hawkins, who recently ended his tenure as Medtronic’s chairman and CEO.